Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more
Oxford Biomedica plc (OXBDF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.014x
Based on the latest financial reports, Oxford Biomedica plc (OXBDF) has a cash flow conversion efficiency ratio of -0.014x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.71 Million) by net assets ($198.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oxford Biomedica plc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Oxford Biomedica plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oxford Biomedica plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxford Biomedica plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
-0.496x |
|
Exmar NV
PINK:EXMRF
|
N/A |
|
Nanjing Toua Hardware&Tools Co.Ltd.
SHE:301125
|
0.032x |
|
Sodick Co., Ltd.
PINK:SDCKF
|
N/A |
|
Probe Metals Inc
OTCQB:PROBF
|
-0.217x |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
0.038x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.247x |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
0.153x |
Annual Cash Flow Conversion Efficiency for Oxford Biomedica plc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Oxford Biomedica plc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.49 Million | $-50.67 Million | -0.838x | -128.62% |
| 2023-12-31 | $77.83 Million | $-28.52 Million | -0.366x | -585.98% |
| 2022-12-31 | $236.19 Million | $-12.62 Million | -0.053x | -139.31% |
| 2021-12-31 | $187.34 Million | $25.45 Million | 0.136x | +391.64% |
| 2020-12-31 | $112.75 Million | $3.12 Million | 0.028x | +159.58% |
| 2019-12-31 | $75.63 Million | $-3.51 Million | -0.046x | -112.52% |
| 2018-12-31 | $34.74 Million | $12.87 Million | 0.370x | -23.58% |
| 2017-12-31 | $6.15 Million | $2.98 Million | 0.485x | +430.87% |
| 2016-12-31 | $12.62 Million | $-1.85 Million | -0.146x | +87.83% |
| 2015-12-31 | $10.89 Million | $-13.12 Million | -1.204x | -359.92% |
| 2014-12-31 | $23.04 Million | $-6.03 Million | -0.262x | +78.86% |
| 2013-12-31 | $8.90 Million | $-11.02 Million | -1.238x | -- |